SeraCare Life Sciences Expands Product Portfolio

SeraCare Life Sciences SRLS today announced that the Company has introduced three new, differentiated panels to its product portfolio -- an HIV/HCV/HBV Nucleic Acid Qualification Panel, an HIV-1 RNA Linearity Panel and an Anti-HIV-2 Performance Panel. "New products play an important role in maintaining our competitive advantage, particularly as the market seeks to consolidate suppliers," said Greg Gould, Interim Chief Executive Officer and Chief Financial Officer. "Continually adding innovative products to our portfolio helps grow our business within our current customer base and creates opportunities to expand into new markets and applications. We look forward to continuing to add to our offerings over the course of the year." New product highlights: The HIV/HCV/HBV Nucleic Acid Qualification Panel is designed to compete favorably in the market by combining all three of the most commonly tested disease markers for both blood-donor screening and diagnostic testing in a single panel. This new panel offers increased fill size and is priced competitively to encourage rapid adoption. The HIV-1 RNA Linearity Panel replaces a previous panel in SeraCare's portfolio and is now quantified in International Units based on the new World Health Organization standards, allowing customers to compare results across platforms. The Anti-HIV-2 Performance Panel upgrades a previous panel to demonstrate results with fourth generation antigen/antibody HIV tests currently on the market. HIV-2 is much rarer than HIV-1, making qualification and acceptance testing with HIV-2 more difficult as materials are harder to find. SeraCare's HIV-2 performance panel provides customers an easy source for HIV-2, uniquely positioning SeraCare to fulfill an unmet need in the marketplace.